Compare Ginkgo Bioworks Holdings Inc (DNA) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs NRG Energy Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.1 (market cap $763.64M), while NRG Energy Inc trades at $107.27 (market cap $22.35B). The key difference: NRG Energy Inc is far larger — about 29.3× Ginkgo Bioworks Holdings Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and NRG Energy Inc for 63 Days on average.
| DNA | NRG | |
|---|---|---|
Market Cap | $763.64M | $22.35B |
Volume | 3,204,177 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $15.83 | $184.03 |
52-Week Low | $5.48 | $95.23 |
Typical Hold Time | 7 Days | 63 Days |
Enterprise Value | $865.59M | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
NRG Energy trades at $107.24, down 1.26% on the day, with a bullish technical signal supported by moving averages. The company shows strong profitability with 26.77% ROE and 2.56% net margin, though recent Q1 and Q2 2026 earnings missed expectations. Revenue growth remains positive, reaching $30.71B in 2025, while valuation metrics show a P/E of 27.69 and P/S of 0.65. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant.
Outlook remains positive with analyst consensus strongly bullish (70% buy ratings) and a $202.90 price target suggesting significant upside. Key risks include rising debt levels (56.42% debt-to-asset ratio) and execution challenges on major capital projects. The company's dual retail/generation model provides stability, but investors should monitor earnings delivery against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
